Providing the first overview of Asia’s emerging biosciences landscape, this timely and important collection brings together ethnographic case studies on biotech endeavors such as genetically modified foods in China, clinical trials in India, blood collection in Singapore and China, and stem-cell research in Singapore, South Korea, and Taiwan. While biotech policies and projects vary by country, the contributors identify a significant trend toward state entrepreneurialism in biotechnology, and they highlight the ways that political thinking and ethical reasoning are converging around the biosciences. As ascendant nations in a region of postcolonial emergence, with an “uncanny surplus” in population and pandemics, Asian countries treat their populations as sources of opportunity and risk. Biotech enterprises are allied to efforts to overcome past humiliations and restore national identity and political ambition, and they are legitimized as solutions to national anxieties about food supplies, diseases, epidemics, and unknown biological crises in the future. Biotechnological responses to perceived risks stir deep feelings about shared fate, and they crystallize new ethical configurations, often re-inscribing traditional beliefs about ethnicity, nation, and race. As many of the essays in this collection illustrate, state involvement in biotech initiatives is driving the emergence of “biosovereignty,” an increasing pressure for state control over biological resources, commercial health products, corporate behavior, and genetic based-identities. Asian Biotech offers much-needed analysis of the interplay among biotechnologies, economic growth, biosecurity, and ethical practices in Asia. Contributors Vincanne Adams Nancy N. Chen Stefan Ecks Kathleen Erwin Phuoc V. Le Jennifer Liu Aihwa Ong Margaret Sleeboom-Faulkner Kaushik Sunder Rajan Wen-Ching Sung Charis Thompson Ara Wilson

After World War II, several late-developing countries registered astonishingly high growth rates under strong state direction, making use of smart investment strategies, turnkey factories, and reverse-engineering, and taking advantage of the postwar global economic boom. Among these economic miracles were postwar Japan and, in the 1960s and 1970s, the so-called Asian Tigers—Singapore, South Korea, and Taiwan—whose experiences epitomized the analytic category of the "developmental state." In Betting on Biotech, Joseph Wong examines the emerging biotechnology sector in each of these three industrial dynamos. They have invested billions of dollars in biotech industries since the 1990s, but commercial blockbusters and commensurate profits have not followed. Industrial upgrading at the cutting edge of technological innovation is vastly different from the dynamics of earlier practices in established industries. The profound uncertainties of life-science-based industries such as biotech have forced these nations to confront a new logic of industry development, one in which past strategies of picking and making winners have given way to a new strategy of throwing resources at what remain very long shots. Betting on Biotech illuminates a new political economy of industrial technology innovation in places where one would reasonably expect tremendous potential—yet where billion-dollar bets in biotech continue to teeter on the brink of spectacular failure.

In Fungible Life Aihwa Ong explores the dynamic world of cutting-edge bioscience research, offering critical insights into the complex ways Asian bioscientific worlds and cosmopolitan sciences are entangled in a tropical environment brimming with the threat of emergent diseases. At biomedical centers in Singapore and China scientists map genetic variants, disease risks, and biomarkers, mobilizing ethnicized "Asian" bodies and health data for genomic research. Their differentiation between Chinese, Indian, and Malay DNA makes fungible Singapore's ethnic-stratified databases that come to "represent" majority populations in Asia. By deploying genomic science as a public good, researchers reconfigure the relationships between objects, peoples, and spaces, thus rendering "Asia" itself as a shifting entity. In Ong's analysis, Asia emerges as a richly layered mode of entanglements, where the population's genetic pasts, anxieties and hopes, shared genetic weaknesses, and embattled genetic futures intersect. Furthermore, her illustration of the contrasting methods and goals of the Biopolis biomedical center in Singapore and BGI Genomics in China raises questions about the future direction of cosmopolitan science in Asia and beyond.

Biotechnology Is At The Heart Of Technology Revolution In Asia Today With Immense Potential In The Pharmaceutical And Agriculture Sectors. This Study Covers Economic And Policy Issues And The Experiences In Biotechnology In Japan, India, Malaysia, The Phillipines, Korea, Bangladesh, Thailand, China And Singapore And Also The International Cooperative Strategies Of Asean And In Europe. This Book Is A Valuable Resource For Governments, Multilateral Institutions, Academics And Practitioners In The Field Of Economic Development And Technology Policy Management.

This work illustrates how Asia is using biology to create innovative products, services and technologies to meet the goals of poverty reduction, food security, livelihood improvement and wealth creation in future years.

In developing countries, traditional fermentation serves many purposes. It can improve the taste of an otherwise bland food, enhance the digestibility of a food that is difficult to assimilate, preserve food from degradation by noxious organisms, and increase nutritional value through the synthesis of essential amino acids and vitamins. Although "fermented food" has a vaguely distasteful ring, bread, wine, cheese, and yogurt are all familiar fermented foods. Less familiar are gari, ogi, idli, ugba, and other relatively unstudied but important foods in some African and Asian countries. This book reports on current research to improve the safety and nutrition of these foods through an elucidation of the microorganisms and mechanisms involved in their production. Also included are recommendations for needed research.

What might COVID-19 mean for, and reveal about, China's place in the world? The coronavirus pandemic started in Wuhan, home to the leading lab studying the SARS virus and bats. Was that pure coincidence? This book explores what we know, and still don't know, about the origins of COVID-19, and how it was handled in China. We may never get all the answers, but much is already clear: China's record as the origin of earlier pandemics, and its struggle to bring contagious diseases under control; its history as both a victim of biological warfare and a developer of deadly bioweapons. When Covid broke out, Wuhan was building science parks to realise Beijing's ambitions in biotech research. Whoever achieves global leadership of the gene-editing industry stands to harvest great power and wealth. China has already challenged Western technological supremacy with 5G and in other industries. Yet this tiny, invisible virus has cruelly exposed a critical flaw in the Chinese political system: obsessive secrecy. The West wanted to trust the PRC, hoping that, as it prospered, it would become an open society. Made in China reveals how Beijing's leaders have betrayed that trust.